Celltrion Group
셀트리온
Korea's leading biosimilar maker, founded 2002. Its Remsima anti-TNF therapy was the world's first biosimilar approved by the European Medicines Agency.
Chairman
Seo Jung-jin
Founded
2002
Headquarters
Seoul, South Korea
Total Mkt Cap
₩45.0T
Affiliates
10
1D (weighted)
-1.49%
Sectors
BioPharmaceuticals
Recent Briefs
0 items
No Celltrion Group briefs yet.
※ Information published on this site may contain errors or delays, and users are solely responsible for any consequences arising from its use.
* Based on KRX